ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SCNI
CLDI (31) PMCB (34) LIMN (35) CRIS (27) ⌘ Pro Terminal →

Scinai Immunotherapeutics Ltd. (SCNI) — RQD Stock Rating Cockpit

$0.47 +0.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.47

Scinai Immunotherapeutics Ltd. (SCNI) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SCNI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SCNI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $0.47 (+0.55% 1D, market cap $1.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SCNI ranks #878 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SCNI compare to CLDI and PMCB in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCNI carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, CLDI (Calidi Biotherapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and PMCB (PharmaCyte Biotech Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -30.2%, cap $3.2M). Among the 5-stock peer group, SCNI leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SCNI?
▼

Per SCNI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611747), Scinai Immunotherapeutics Ltd. generated $1.3M in revenue (+99.2% YoY), -$8.3M in net income, and -$6.1M in free cash flow against $11.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.47 (-0.09%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (8)Whales (3)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.8% Base Target
$16 Bull$0 Base$0 Bear
📬 FREE SCNI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SCNI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY SCNI SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$1.23-44.7% Next Q
Q2 (-2Q)
33
Grade E$0.68-22.1% Next Q
Q3 (-1Q)
31
Grade E$0.53-11.3% Next Q
Current
28
Grade E$0.47-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SCNI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SCNI currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.42) and Max Pain ($0.49) forces dealer call-delta covering toward $16.28.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SCNI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SCNI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
25.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $0$0.47H: $16
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 14 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on SCNI

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with -30.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (20)

6/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like SCNI
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCNI)

  • ✓Walkthrough of SCNI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SCNI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -92.71%⚡ TESTING RESISTANCE
2026-11-03O $0.52H $0.52L $0.47C $0.47VOL 53.0K
RES: $1.00SUP: $0.43SMA50: $1.42SMA200: $4.38
$11.75$8.69$5.63$2.58$-0.48RES $1.00SUP $0.43$0.472026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCNI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SCNI Butterfly Map → + Track SCNI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +99.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SCNI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SCNI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SCNI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCNI)

Health Care Rank #878 of 1015 ⚔️ CLDI vs SCNI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SCNI vs. CLDI, PMCB, LIMN, CRIS)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Scinai Immunotherapeutics Ltd. (SCNI) ranks #878 by composite RQD confidence (28/100, grade E) and #1011 by equity capitalization ($1.2M). Within this direct 5-issuer industry benchmark cohort, SCNI leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. LIMN currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with SCNI at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SCNI ACTIVE
Scinai Immunotherapeutics Ltd.
E 28/100 — -30.0% -35.0% +0.55% $1.2M Benchmark Subject
CLDI
Calidi Biotherapeutics Inc.
E 31/100 — — -35.0% -4.36% $2.5M /cldi-vs-scni →
PMCB
PharmaCyte Biotech Inc.
E 34/100 — — -30.2% +2.71% $3.2M /pmcb-vs-scni →
LIMN
Liminatus Pharma Inc. (Class A)
D- 35/100 — — -35.0% -10.64% $3.8M /limn-vs-scni →
CRIS
Curis Inc.
E 27/100 — — -35.0% +10.17% $4.0M /cris-vs-scni →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001611747 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scinai Immunotherapeutics Ltd. (SCNI) reported GAAP revenue of $1.3M (+99.2% vs. FY2024 revenue of $658.0K , and -95.2% cumulative change since FY2023) , GAAP net income of -$8.3M, operating cash flow of -$6.0M, and free cash flow of -$6.1M (+4.6% YoY). On the balance sheet, SCNI closed FY2025 with $11.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.3M -$8.3M -$6.0M -$6.1M $11.6M —
FY2024 (FY) 2024-12-31 $658.0K $4.8M -$6.3M -$6.3M $13.4M —
FY2023 (FY) 2023-12-31 $27.2M -$6.5M -$9.4M -$9.4M — —

3. SCNI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCNI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $0.47 (+0.55% 1D, market cap $1.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SCNI ranks #878 in composite RQD confidence.

How does SCNI compare to CLDI and PMCB in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCNI carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, CLDI (Calidi Biotherapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and PMCB (PharmaCyte Biotech Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -30.2%, cap $3.2M). Among the 5-stock peer group, SCNI leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCNI?

Per SCNI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611747), Scinai Immunotherapeutics Ltd. generated $1.3M in revenue (+99.2% YoY), -$8.3M in net income, and -$6.1M in free cash flow against $11.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCNI trading relative to its 50-day, 200-day, and 52-week technical levels?

SCNI last traded at $0.47 (+0.55% on volume of 167,614 shares), positioning the stock -66.90% below its 50-day simple moving average ($1.42) and -89.27% below its 200-day simple moving average ($4.38). Across its 52-week range of $0.47 to $15.50, SCNI sits at the 0.0% percentile with a 14-day RSI of 25.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.53).

Direct Sub-Reports: SCNI RQD Cockpit SCNI 12M Forecast SCNI Earnings & Move SCNI Dividends & DRIP SCNI Insiders & 13F SCNI Whale Options SCNI Profit Sankey SCNI News & Why
ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

SCNI — Scinai Immunotherapeutics Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Scinai Immunotherapeutics Ltd. (SCNI) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.47 (+0.55% 1D, market capitalization $1.2M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Scinai Immunotherapeutics Ltd. (SCNI) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. It is a biotechnology company with a market capitalization of $0.0B on the profile basis. Reported revenue of $1.3M in FY 2025 is the only indicator of commercial activity.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Scinai Immunotherapeutics Ltd. (SCNI) reported $1.3M in annual revenue (up from $658.0K in FY2024, +99.2% YoY) and -$8.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($27.2M revenue, -$6.5M net income) through FY2025, SCNI scaled operating cash flow to -$6.0M and free cash flow to -$6.1M, backed by $11.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.47 – $15.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or proprietary links are recorded. The headlines do suggest a manufacturing dependency: the financing is described as supporting manufacturing expansion, and a subsidiary has a manufacturing agreement with a U.S. Drugmaker. A prospective investor should watch whether the manufacturing and customer-order pipeline translates into recognized revenue, since the financials show revenue of only $1.3M against operating losses near -$7.5M. Sector-wide biotech financing conditions would also affect a company that depends on repeated equity raises, but no sector correlation data is provided.

  • Key Question #1: Can SCNI sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.3M and free cash flow of -$6.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SCNI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SCNI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Scinai Immunotherapeutics Ltd. (SCNI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SCNI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SCNI Bull vs. Bear Conversation Board — What's Your Call at $0.47?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SCNI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SCNI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $0.58 (+23.4%)
📌 Pinned Debate

Committed customer orders reached about $7.6 million, up about 300%, the strongest operational datapoint in the feed.

Here is why I am bullish on SCNI here at $0.47: Committed customer orders reached about $7.6 million, up about 300%, the strongest operational datapoint in the feed.. Compare SCNI's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $0.45 are getting bought.

ArenaChamp_24 🐂 BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (-30.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $0.40 (-14.9%)
Spot @ $0.47

Operating losses of -$7.5M against $1.3M revenue, negative FCF in every period, and a $4M financing with shares falling.

Careful chasing SCNI at $0.47. Operating losses of -$7.5M against $1.3M revenue, negative FCF in every period, and a $4M financing with shares falling.. Gross margin is -30.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.40 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%